PFE  Pfizer Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.085 (+0.30%)

Growth Price

Undervalued by 7.30%

Stability Price

Overvalued by 59.12%

Company Metrics

  • 17.76 P/E
  • 3.56 P/S
  • 2.34 P/B
  • 1.592 EPS
  • 11.61% Cash ROIC
  • 1.39 Cash Ratio
  • 1.02 / 3.61% Dividend
  • 24.62M Avg. Vol.
  • 179.9B Market Cap.

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Can This 1 Breast Cancer Drug Turn Pfizer Inc. Into a Growth Stock?
Motley Fool - Oct 20, 2014
Big Pharma is undergoing a radical face-lift due to the avalanche of top-selling drugs losing patent protection. The consequences of the aptly named "patent cliff" have been widespread and immense in scope.
Pfizer Now #16 Largest Company, Surpassing AT&T
Forbes - 2 hours ago
Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning ...
AntiCancer, Inc. v. Pfizer, Inc. (Fed. Cir. 2014)
JD Supra (press release) - 15 hours ago
It is with this backdrop that the Federal Circuit decided the Anticancer, Inc. v. Pfizer, Inc. case on Monday, October 20, 2014.
Should Pfizer Inc. Buy Actavis plc?
Motley Fool - Sep 25, 2014
Earlier this year, a media circus erupted over Pfizer's reported interest in AstraZeneca (NYSE: AZN ) . The deal would have exceeded $100 billion and created a company roughly the same size as Johnson & Johnson. AstraZeneca brass, however, felt the ...
Pfizer Inc. Is Kicking The Tires At Actavis PLC - Benzinga
Pfizer Said to Have Approached Actavis About Possible Deal - Bloomberg
Pfizer Inc. (PFE): Why You Should Sell the Stock [AstraZeneca plc (ADR)]
ETF Daily News - Oct 15, 2014
buyers and sellers Lawrence Meyers: Pfizer Inc. (NYSE:PFE) is the country's largest prescription drug maker, has strong free cash flow, lots of cash, the third-highest dividend yield among the 30 Dow stocks, is attractively valued compared to its peer ...
Multiple Contraction Can Hit Pfizer (PFE) - Seeking Alpha (registration)
Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?
Motley Fool - Oct 7, 2014
PCSK9 inhibitors, and their potential sales, have garnered a lot of interest from investors Pfizer's (NYSE: PFE ) Lipitor peaked at well over $10 billion in annual sales.
The Most Important Number You Need to Know Before Buying Pfizer Inc. Stock
Motley Fool - Oct 6, 2014
Every company has one number that defines its success more than any other. For Pfizer (NYSE: PFE ) , the world's largest pharmaceutical company, that number is... $10.7 billion. Pfizer has four blockbuster drugs coming off-patent in the United States ...
One Put, One Call Option To Know About for Pfizer
Forbes - Oct 20, 2014
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer Pfizer Inc (NYSE: PFE). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
What Happens If Pfizer Inc. Doesn't Come Back For AstraZeneca plc?
The Motley Fool UK - Oct 14, 2014
Unfortunately, these figures imply that if Pfizer does not come back for Astra, Astra's shares will fall. If the company's valuation were to fall to a level similar to the rest of the sector, the shares would only be worth 3,523p. With earnings ...
AstraZeneca share price: Analysts see drugmaker as viable takeover target - iNVEZZ
Exxon Mobil Corporation, The Procter & Gamble Company, Pfizer Inc.: The Case ...
ETF Daily News - Oct 21, 2014
In our tireless efforts to always beat the market, we're constantly searching for outside-the-box, off-the-grid, contrarian investment plays that Wall Street has “overlooked.